File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Shifting the paradigm for maintenance therapy for non-small cell lung cancer

TitleShifting the paradigm for maintenance therapy for non-small cell lung cancer
Authors
KeywordsCarcinoma, non-small-cell lung cancer
Lung neoplasms
Prognosis
Survival rate
Treatment outcome
Issue Date2010
PublisherScientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/
Citation
Journal of the Hong Kong College of Radiologists, 2010, v. 13 n. 3, Suppl., p. 16-21 How to Cite?
AbstractSystemic chemotherapy has been the standard treatment for advanced I metastatic non-small-cell lung cancer, particularly in those who do not harbour an epidermal growth factor receptor mutation. In the last decade, there was no established evidence to justify the use of more than 4 to 6 cycles of chemotherapy. However, the use of maintenance systemic chemotherapy and more recently targeted therapy for those who do not show evidence of benefit after standard chemotherapy have been demonstrated to delay progression and more importantly prolong survival. Use of pemetrexed after standard non-pemetrexed chemotherapy has brought an improvement in median survival by 2.8 months. The use of more easily administered erlotinib as maintenance therapy after chemotherapy has been shown to improve the median survival by 1.0 month. Use of bevacizumab, an anti-vascular endothelial growth factor receptor monoclonal antibody, combined with standard chemotherapy to start with also appears to be safe and efficacious. This article elaborates on the rationale, use, and future directions of maintenance therapy after standard chemotherapy for advanced I metastatic non-small-cell lung cancer. © 2010 Hong Kong College of Radiologists. 全身化療已成為晚期或轉移性非小細胞肺癌的標準治療,尤期是那些沒有表皮生長因子受體突變的 病人。過去十年都沒有確實證據支持進行多於四至六個周期的化療。可是已有證據顯示全身性維持 化療以及近期的標靶治療,可以為那些未受惠於標準化療的病人延緩病情惡化,更重要的是可以延 長他們的生存期。病人接受完非培美曲塞的標準化療後再服用培美曲塞(pemetrexed)可以把生存期 中位數增加2.8個月。化療後以簡單易用的埃羅替尼(erlotinib)作維持治療亦可把生存期中位數增加 1.0個月。VEGF抗體貝伐單抗(bevacizumab)結合標準化療似乎同樣安全有效。對於晚期或轉移性 非小細胞肺癌的病人接受完標準治療後所進行的維持治療,本文闡述其理念、用途及未來的發展方 向。
Persistent Identifierhttp://hdl.handle.net/10722/139112
ISSN

 

DC FieldValueLanguage
dc.contributor.authorLee, VHFen_US
dc.date.accessioned2011-09-23T05:45:08Z-
dc.date.available2011-09-23T05:45:08Z-
dc.date.issued2010en_US
dc.identifier.citationJournal of the Hong Kong College of Radiologists, 2010, v. 13 n. 3, Suppl., p. 16-21en_US
dc.identifier.issn1029-5097-
dc.identifier.urihttp://hdl.handle.net/10722/139112-
dc.description.abstractSystemic chemotherapy has been the standard treatment for advanced I metastatic non-small-cell lung cancer, particularly in those who do not harbour an epidermal growth factor receptor mutation. In the last decade, there was no established evidence to justify the use of more than 4 to 6 cycles of chemotherapy. However, the use of maintenance systemic chemotherapy and more recently targeted therapy for those who do not show evidence of benefit after standard chemotherapy have been demonstrated to delay progression and more importantly prolong survival. Use of pemetrexed after standard non-pemetrexed chemotherapy has brought an improvement in median survival by 2.8 months. The use of more easily administered erlotinib as maintenance therapy after chemotherapy has been shown to improve the median survival by 1.0 month. Use of bevacizumab, an anti-vascular endothelial growth factor receptor monoclonal antibody, combined with standard chemotherapy to start with also appears to be safe and efficacious. This article elaborates on the rationale, use, and future directions of maintenance therapy after standard chemotherapy for advanced I metastatic non-small-cell lung cancer. © 2010 Hong Kong College of Radiologists. 全身化療已成為晚期或轉移性非小細胞肺癌的標準治療,尤期是那些沒有表皮生長因子受體突變的 病人。過去十年都沒有確實證據支持進行多於四至六個周期的化療。可是已有證據顯示全身性維持 化療以及近期的標靶治療,可以為那些未受惠於標準化療的病人延緩病情惡化,更重要的是可以延 長他們的生存期。病人接受完非培美曲塞的標準化療後再服用培美曲塞(pemetrexed)可以把生存期 中位數增加2.8個月。化療後以簡單易用的埃羅替尼(erlotinib)作維持治療亦可把生存期中位數增加 1.0個月。VEGF抗體貝伐單抗(bevacizumab)結合標準化療似乎同樣安全有效。對於晚期或轉移性 非小細胞肺癌的病人接受完標準治療後所進行的維持治療,本文闡述其理念、用途及未來的發展方 向。zh_HK
dc.languageengen_US
dc.publisherScientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/en_US
dc.relation.ispartofJournal of the Hong Kong College of Radiologistsen_US
dc.subjectCarcinoma, non-small-cell lung cancer-
dc.subjectLung neoplasms-
dc.subjectPrognosis-
dc.subjectSurvival rate-
dc.subjectTreatment outcome-
dc.titleShifting the paradigm for maintenance therapy for non-small cell lung canceren_US
dc.typeArticleen_US
dc.identifier.emailLee, VHF: vhflee@hku.hken_US
dc.identifier.authorityLee, VHF=rp00264en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.scopuseid_2-s2.0-79952059424-
dc.identifier.hkuros194420en_US
dc.identifier.volume13en_US
dc.identifier.issue3, Suppl.en_US
dc.identifier.spage16en_US
dc.identifier.epage21en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats